Wayfinder Biosciences focuses on addressing the challenge of "undruggable" targets in oncology by targeting RNA, which plays a crucial role in various cellular processes. The company recognizes that a significant portion of cellular proteins, estimated at up to 85%, cannot be effectively targeted with traditional small molecules. By developing small molecule assets that target the RNA of disease-causing genes, Wayfinder aims to prevent the production of harmful proteins at their source. This innovative approach positions RNA as a promising target for therapeutic intervention, particularly in the context of cancer.

The company's technology platform integrates proprietary experimental methods with advanced artificial intelligence and machine learning (AI/ML) for virtual screening. Central to this platform are Wayfinder's RNA sensors, which are specifically designed to provide quantitative signals when small molecules successfully modulate the structure of target RNA. This data-driven methodology allows Wayfinder to derive generalizable principles for designing functional molecules that not only bind to RNA but also influence its structure and function. By collaborating with pharmaceutical and biotech partners, Wayfinder seeks to advance RNA-targeting small molecule therapies across various therapeutic areas, including oncology, neurodegeneration, and rare diseases.

United States

We are developing a platform for discovery of RNA-targeting small molecules to treat genetic diseases, neurodegeneration and cancer. We combine a proprietary high-throughput screening platform with machine learning models and unique datasets to accelerate development of drugs for previously undruggable targets. https://wayfinderbio.com

Wayfinder Biosciences

Company Details